Literature DB >> 24008815

World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base.

F Estelle R Simons1, Ledit R F Ardusso, Vesselin Dimov, Motohiro Ebisawa, Yehia M El-Gamal, Richard F Lockey, Mario Sanchez-Borges, Gian Enrico Senna, Aziz Sheikh, Bernard Y Thong, Margitta Worm.   

Abstract

The World Allergy Organization (WAO) Guidelines for the assessment and management of anaphylaxis are a widely disseminated and used resource for information about anaphylaxis. They focus on patients at risk, triggers, clinical diagnosis, treatment in health care settings, self-treatment in the community, and prevention of recurrences. Their unique strengths include a global perspective informed by prior research on the global availability of essentials for anaphylaxis assessment and management and a global agenda for anaphylaxis research. Additionally, detailed colored illustrations are linked to key concepts in the text [Simons et al.: J Allergy Clin Immunol 2011;127:593.e1-e22]. The recommendations in the original WAO Anaphylaxis Guidelines for management of anaphylaxis in health care settings and community settings were based on evidence published in peer-reviewed, indexed medical journals to the end of 2010. These recommendations remain unchanged and clinically relevant. An update of the evidence base was published in 2012 [Simons et al.: Curr Opin Allergy Clin Immunol 2012;12:389-399]. In 2012 and early 2013, major advances were reported in the following areas: further characterization of patient phenotypes; development of in vitro tests (for some allergens) that help distinguish clinical risk of anaphylaxis from asymptomatic sensitization; epinephrine (adrenaline) research, including studies of a new epinephrine auto-injector for use in community settings, and randomized controlled trials of immunotherapy to prevent food-induced anaphylaxis. Despite these advances, the need for additional prospective studies, including randomized controlled trials of interventions in anaphylaxis is increasingly apparent. This 2013 Update highlights publications from 2012 and 2013 that further contribute to the evidence base for the recommendations made in the original WAO Anaphylaxis Guidelines. Ideally, it should be used in conjunction with these Guidelines and with the 2012 Guidelines Update.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24008815     DOI: 10.1159/000354543

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  49 in total

1.  Reactions of Buckwheat-Hypersensitive Patients during Oral Food Challenge Are Rare, but Often Anaphylactic.

Authors:  Noriyuki Yanagida; Sakura Sato; Kyohei Takahashi; Ken-Ichi Nagakura; Kiyotake Ogura; Tomoyuki Asaumi; Motohiro Ebisawa
Journal:  Int Arch Allergy Immunol       Date:  2017-03-08       Impact factor: 2.749

Review 2.  Adverse reactions to snake antivenom, and their prevention and treatment.

Authors:  H Asita de Silva; Nicole M Ryan; H Janaka de Silva
Journal:  Br J Clin Pharmacol       Date:  2015-09-16       Impact factor: 4.335

Review 3.  The Epidemiology of Anaphylaxis.

Authors:  Joyce E Yu; Robert Y Lin
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

4.  Biphasic and protracted anaphylaxis to iodinated contrast media.

Authors:  Tae-Hyung Kim; Soon Ho Yoon; Suh-Young Lee; Young Hun Choi; Chang Min Park; Hye-Ryun Kang; Sang-Heon Cho
Journal:  Eur Radiol       Date:  2017-09-27       Impact factor: 5.315

Review 5.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

6.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.

Authors:  Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2016-10-12       Impact factor: 4.084

7.  Risk Factors for Severe Reactions during Double-Blind Placebo-Controlled Food Challenges.

Authors:  Noriyuki Yanagida; Sakura Sato; Tomoyuki Asaumi; Kiyotake Ogura; Motohiro Ebisawa
Journal:  Int Arch Allergy Immunol       Date:  2017-04-06       Impact factor: 2.749

Review 8.  [Catecholamines: pro and contra].

Authors:  R Riessen; O Tschritter; U Janssens; M Haap
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-03-25       Impact factor: 0.840

9.  Insulin-like growth factor-2 enhances functions of antigen (Ag)-specific regulatory B cells.

Authors:  Xiao-Rui Geng; Gui Yang; Meng Li; Jiang-Ping Song; Zhi-Qiang Liu; Shuqi Qiu; Zhigang Liu; Ping-Chang Yang
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

Review 10.  Unusual reactions to hymenoptera stings: what should we keep in mind?

Authors:  Ervin Ç Mingomataj; Alketa H Bakiri; Alkerta Ibranji; Gunter J Sturm
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.